Advertisement

Search Results

Advertisement



Your search for Eric Van Cutsem, MD, PhD, and Axel Grothey, MD,Eric Van Cutsem, MD, PhD, and Axel Grothey, MD matches 3 pages

Showing 1 - 3


colorectal cancer
gastrointestinal cancer
immunotherapy

Triplet Therapy Poses a Triple Threat to BRAF-Mutated Colorectal Cancers

Triplet therapy that inhibits the BRAF, MEK, and epidermal growth factor receptor (EGFR) pathways appears promising in BRAF-mutated colorectal cancer, a malignancy that typically does not respond to BRAF inhibition alone. Early results from the BEACON CRC study showed a 48% response rate and an...

colorectal cancer

Eric Van Cutsem, MD, PhD, and Axel Grothey, MD, on HERACLES and Other Colorectal Cancer Findings

Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, and Axel Grothey, MD, of the Mayo Clinic, discuss the Italian-led study on trastuzumab and lapatinib in HER2-amplified metastatic colorectal as well as other colorectal cancer findings discussed at ASCO (Abstract 3508).

Expert Point of View: Axel Grothey, MD and Eric Van Cutsem, MD, PhD

Two gastrointestinal cancer experts commented on the findings in interviews with The ASCO Post. Axel Grothey, MD, Professor of Oncology at the Mayo Clinic, Rochester, Minnesota, noted, “The PEAK and SPIRITT trial were decently designed, decently powered randomized phase II trials, and the results...

Advertisement

Advertisement



Advertisement